Jeff Alexander leads Lilly Gateway Labs at Breakthrough, where he supports an innovation community for early-stage companies and drives strategic engagement with Philadelphia biotechnology.

Before joining Lilly, Jeff spent six years at Spark Therapeutics advancing non-clinical research and drug development strategy for liver-directed gene therapy. His work contributed directly to Phase 3 entry of Spark's hemophilia A gene therapy program and produced novel published approaches to overcoming pre-existing AAV antibody immunity.

Jeff holds a Ph.D. in Biomedical Science from UCSF and a B.A. in Genetics and Physics from Rutgers University.